Intervention
Apixaban
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 26 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
26 shownTreatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersNCT07493304 · 2026-08-26
RECRUITINGApixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer TreatmentNCT07160686 · 2026-04-28
RECRUITINGApixaban-PK Trial: Preventing Portal Hypertension Complications in CirrhosisNCT07521332 · 2026-04-01
RECRUITINGApixaban in ThrombocytopeniaNCT06886516 · 2025-02-28
RECRUITINGReduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic MalignanciesNCT07270263 · 2024-11-22
RECRUITINGBariatric Surgery and Pharmacokinetics of ApixabanNCT03448783 · 2018-01-02
RECRUITINGEdoxaban Versus Apixaban in Cancer-Associated Venous ThromboembolismNCT07852637 · 2026-11-01
NOT_YET_RECRUITINGExtended Prophylactic Anticoagulation Following Spinal Surgery for Metastatic DiseaseNCT07713875 · 2026-08-01
NOT_YET_RECRUITINGSWITCH: Apixaban vs Vitamin K in HM3NCT07471139 · 2026-08-01
NOT_YET_RECRUITINGA Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTENCT05171049 · 2022-05-05
TERMINATEDEvaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist DevicesNCT04865978 · 2021-12-14
COMPLETEDEffects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF TrialNCT04696120 · 2021-03-02
UNKNOWNApixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT）NCT04645550 · 2020-11-22
COMPLETEDEffectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With MedicareNCT04681482 · 2020-11-02
COMPLETEDPharmacokinetics of Apixaban in Patients Undergoing PancreaticoduodenectomyNCT04191928 · 2020-03-03
COMPLETEDStrategies for the Management of Atrial Fibrillation in patiEnts Receiving DialysisNCT03987711 · 2019-12-10
COMPLETEDStandard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary EmbolismNCT03988842 · 2019-07-25
TERMINATEDApixaban for Intrahepatic Non Cirrhotic Portal HypertensionNCT04007289 · 2019-06-24
ACTIVE_NOT_RECRUITINGApixaban Pharmacokinetics in Bariatric Patients (APB)NCT02406885 · 2017-07-19
COMPLETEDApixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation TherapyNCT03080883 · 2017-07-14
COMPLETEDCompare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)NCT02933697 · 2017-06-20
COMPLETEDDrug Interaction Study of Apixaban With Cyclosporine and TacrolimusNCT03083782 · 2017-04-18
COMPLETEDDirect Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in CancerNCT02744092 · 2016-12-13
COMPLETEDApixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous ThromboembolismNCT02585713 · 2015-11-20
COMPLETEDORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)NCT02935855 · 2015-09-01
COMPLETEDA Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) CancerNCT00320255 · 2006-06-01
COMPLETEDCommon conditions
Pulmonary Embolism6Venous Thromboembolism5Atrial Fibrillation3Deep Vein Thrombosis3Heart Failure3Cancer2Cerebral Vein Thrombosis2Cirrhosis2Deep Vein Thrombosis (DVT)2Obesity2Portal Vein Thrombosis2Pulmonary Embolism (PE)2Venous Thromboembolism (VTE)2Active Cancer1Anticoagulants1Ascites1Bariatric Surgery1Bleeding1Blood Clot1Cerebrovascular Disease1Deep Venous Thrombosis1Diabetes1DVT1End Stage Renal Failure on Dialysis1End-stage Kidney Disease1
Leading sponsors
Academic and Community Cancer Research United
2
Thomas Jefferson University
2
Alliance Foundation Trials, LLC.
1
Anthos Therapeutics, Inc.
1
Asian Institute Of Medical Sciences
1
Assistance Publique - Hôpitaux de Paris
1
Atrial Fibrillation Network
1
Bristol-Myers Squibb
1
Columbia University
1
James Bayley
1
Johns Hopkins University
1
Korea University Guro Hospital
1
Medical University of Gdansk
1
Northern Jiangsu People's Hospital
1
Norwegian University of Science and Technology
1
Trial status mix
COMPLETED13
RECRUITING6
NOT_YET_RECRUITING3
TERMINATED2
ACTIVE_NOT_RECRUITING1
UNKNOWN1
Phase mix
PHASE38
PHASE47
PHASE24
NA2
PHASE12
EARLY_PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.